Intermediate Renal Outcomes, Kidney Failure, and Mortality in Obese Kidney Donors.

Autor:	Ibrahim HN; Department of Medicine, Houston Methodist Hospital, Houston, Texas., Murad DN; Department of Medicine, Houston Methodist Hospital, Houston, Texas., Hebert SA; Department of Medicine, Houston Methodist Hospital, Houston, Texas., Adrogue HE; Department of Medicine, Houston Methodist Hospital, Houston, Texas., Nguyen H; Department of Medicine, Houston Methodist Hospital, Houston, Texas., Nguyen DT; Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, Texas., Matas AJ; Department of Surgery, University of Minnesota, Minneapolis, Minnesota., Graviss EA; Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, Texas.; Department of Surgery, Houston Methodist Hospital, Houston, Texas.
Jazyk:	angličtina
Zdroj:	Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2021 Nov; Vol. 32 (11), pp. 2933-2947. Date of Electronic Publication: 2021 Oct 21.
DOI:	10.1681/ASN.2021040548
Abstrakt:	Background: Obesity is associated with the two archetypal kidney disease risk factors: hypertension and diabetes. Concerns that the effects of diabetes and hypertension in obese kidney donors might be magnified in their remaining kidney have led to the exclusion of many obese candidates from kidney donation. Methods: We compared mortality, diabetes, hypertension, proteinuria, reduced eGFR and its trajectory, and the development of kidney failure in 8583 kidney donors, according to body mass index (BMI). The study included 6822 individuals with a BMI of <30 kg/m 2 , 1338 with a BMI of 30-34.9 kg/m 2 , and 423 with a BMI of ≥35 kg/m 2 . We used Cox regression models, adjusting for baseline covariates only, and models adjusting for postdonation diabetes, hypertension, and kidney failure as time-varying covariates. Results: Obese donors were more likely than nonobese donors to develop diabetes, hypertension, and proteinuria. The increase in eGFR in obese versus nonobese donors was significantly higher in the first 10 years (3.5 ml/min per 1.73m 2 per year versus 2.4 ml/min per 1.73m 2 per year; P <0.001), but comparable thereafter. At a mean±SD follow-up of 19.3±10.3 years after donation, 31 (0.5%) nonobese and 12 (0.7%) obese donors developed ESKD. Of the 12 patients with ESKD in obese donors, 10 occurred in 1445 White donors who were related to the recipient (0.9%). Risk of death in obese donors was not significantly increased compared with nonobese donors. Conclusions: Obesity in kidney donors, as in nondonors, is associated with increased risk of developing diabetes and hypertension. The absolute risk of ESKD is small and the risk of death is comparable to that of nonobese donors. (Copyright © 2021 by the American Society of Nephrology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu